Genentech Seeks Partners For Biomarker-Driven Drug Development Beyond Oncology

Roche subsidiary hopes recent deals with 23andMe and Human Longevity for whole genome sequencing will help identify targets and biomarkers for Parkinson's disease and other non-cancer conditions. Firm also is taking a personalized medicine approach to development of treatments for pain, macular degeneration and asthma.

Genentech Inc. is looking for business development deals and licensing opportunities that will continue the biotech giant's expansion of its biomarker-based approach to drug development beyond the oncology setting.

"We like to let the world know that we're open for business," Genentech Senior Director-Business Development Tom Zioncheck said. "We're looking and seeking collaborations and good science all over the...

More from Clinical Trials

More from R&D